Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Keyphrases

• Seizure 100%
• Placebo-controlled 100%
• Phase II Trial 100%
• Randomized Double-blind 100%
• Cannabidiol 100%
• Lennox-Gastaut Syndrome 100%
• Drop Seizures 41%
• Placebo Groups 33%
• Adverse Events 25%
• Treatment-resistant 16%
• Placebo 16%
• One Dose 16%
• Treatment Duration 16%
• Efficacy Data 16%
• Voice User Interface 8%
• Severe Disease 8%
• Age Groups 8%
• Clinical Site 8%
• Patient Caregivers 8%
• Epileptic Encephalopathy 8%
• Antiepileptic Drugs 8%
• Randomized Placebo-controlled Trial 8%
• Long-term Efficacy 8%
• Poland 8%
• Treatment Group 8%
• Diarrhea 8%
• Add-on Therapy 8%
• Netherlands 8%
• Long-term Safety 8%
• Safety Analysis 8%
• Generalized Seizures 8%
• Group Assignment 8%
• Seizure Frequency 8%
• Vomiting 8%
• Percentage Reduction 8%
• Electroencephalogram 8%
• Baseline Period 8%
• Change from Baseline 8%
• Somnolence 8%
• Open-label Extension 8%
• Wave Pattern 8%
• Median Difference 8%
• Spike Waveform 8%
• Anticonvulsant Therapy 8%
• Monthly Frequency 8%
• Pyrexia 8%
• Decreased Appetite 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Cannabidiol 100%
• Placebo 100%
• Lennox Gastaut Syndrome 100%
• Adverse Event 25%
• Add on Therapy 8%
• Anticonvulsant Therapy 8%
• Anticonvulsive Agent 8%
• Fever 8%
• Brain Disease 8%
• Diarrhea 8%
• Tonic Clonic Seizure 8%
• Decreased Appetite 8%
• Somnolence 8%